… the efficacy and safety of anlotinib, a … anlotinib between 2018 and 2020 were evaluated.
Results: Forty-one and 30 patients were enrolled to evaluate the efficacy and safety of anlotinib, …

… Anlotinib is a novel multitarget tyrosine kinase inhibitor. ALTER0703 study was conducted to
assess efficacy and safety of anlotinib … assess the efficacy and safety of anlotinib in patients …

… Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus
PD-… All patients received anlotinib and PD-1 inhibitor. The primary endpoints were objective …

… s efficacy in advanced non–small cell lung cancer (NSCLC). Objective To investigate the
efficacy of anlotinib … trial designed to evaluate the efficacy and safety of anlotinib in patients with …

… All the patients were administered with anlotinib monotherapy. Demographic data of the
patients were collected; effectiveness and safety profile during anlotinib monotherapy were …

… Anlotinib not only improves PFS and DCR significantly, but also presents good safety in
patients with LMS, which suggests that anlotinib could be an option for LMS patients. …

… In theory, physicians can gain long-term tumor control with anlotinib in certain advanced …
taken anlotinib regularly for more than 12 months. Their general information, clinical efficacy…

… efficacy and safety of anlotinib. As no standard third-line treatment is available for patients
with advanced NSCLC, anlotinib … estimate the safety and efficacy of anlotinib monotherapy for …

… Anlotinib has been approved as the third-line or beyond … of anlotinib in the maintenance
therapy of ES-SCLC. Therefore, this study aims to evaluate the efficacy and safety of anlotinib …

… In this study, we assessed the efficacy and safety of anlotinib for SCLC patients after first-line
treatments. After including 13 studies, the meta-analysis results showed that the overall …